Abeona Therapeutics.jpg
Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates
12 nov. 2019 16h30 HE | Abeona Therapeutics Inc.
Submitted additional EB-101 transport stability data to FDA in response to Clinical Hold Letter; CMC clearance for pivotal VIITALTM Phase 3 trial anticipated in Q4 2019Publication of positive...
Abeona Therapeutics.jpg
Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
15 oct. 2019 09h15 HE | Abeona Therapeutics Inc.
Sustained wound healing and favorable safety profile observed at three years post-treatment Durable wound healing in large, disabling, chronic wounds EB-101 associated with long-term molecular...
Abeona Therapeutics.jpg
Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
08 mai 2019 08h30 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data...
Abeona Therapeutics.jpg
Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
08 janv. 2019 13h00 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics.jpg
Abeona Announces Participation at Upcoming Conferences
04 sept. 2018 08h45 HE | Abeona Therapeutics Inc.
Citi's 13th Annual Biotech Conference - September 5-6th in Boston, MAJefferies Gene Therapy Summit - September 27th in New York, NY NEW YORK and CLEVELAND, Sept. 04, 2018 (GLOBE NEWSWIRE)...
Abeona Therapeutics.jpg
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
09 août 2018 16h20 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics.jpg
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
06 juin 2018 08h45 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 06, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
06 oct. 2017 08h25 HE | Abeona Therapeutics Inc
--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
28 sept. 2017 08h32 HE | Abeona Therapeutics Inc
--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...